Category Archives: Contrast Agents

Iodine 131 MIBG
1
Mar

Overview

Iodine 131 metaiodobenzylguanidine is a norepinephrine analog labeled with I 131 used for diagnostic imaging and targeted radiotherapy in select neuroendocrine tumors.

Properties

I 131 emits beta and gamma radiation enabling both therapeutic effect and gamma imaging; uptake reflects catecholamine transporter activity.

Uses

Used for localization and treatment of pheochromocytoma, paraganglioma and some neuroblastomas under specialized protocols.

Safety

Significant radiation dose requires inpatient isolation for therapy doses and strict radiological safety, thyroid blockade and patient counseling.

Gadoversetamide
1
Mar

Overview

Gadoversetamide is a linear gadolinium chelate that was used for contrast enhanced MRI studies and provided extracellular distribution for lesion detection.

Properties

Linear chelate structure with moderate relaxivity and extracellular distribution similar to other conventional MRI contrast agents.

Uses

Historically used for brain, spine and body MRI to improve lesion conspicuity and vascular imaging.

Safety

Linear structure is associated with higher risk of gadolinium deposition and NSF in severe renal impairment; current practice often favors macrocyclic agents.

Manganese dipyridoxyl diphosphate Mn DPDP
22
Feb

Overview

Mn DPDP is a manganese based MRI contrast agent that provided hepatocyte uptake and T1 shortening for liver lesion characterization.

Properties

Manganese acts as a paramagnetic ion producing T1 shortening; agent had partial hepatocellular uptake and biliary excretion.

Uses

Used for liver MRI to improve detection and characterization of focal hepatic lesions when available.

Safety

Use limited by availability and concerns about manganese toxicity in severe hepatic dysfunction; follow regulatory status and local availability.

Technetium 99m HMPAO
22
Feb

Overview

Technetium 99m HMPAO is a lipophilic radiopharmaceutical used for brain perfusion imaging and for labeling leukocytes in infection imaging.

Properties

Tc 99m HMPAO crosses the blood brain barrier transiently and is retained in brain tissue proportional to regional blood flow; emits gamma photons for SPECT.

Uses

Used for cerebral perfusion SPECT in stroke and dementia evaluation and for leukocyte labeling to localize infection or inflammation.

Safety

Radiation exposure is low but present; follow nuclear medicine safety protocols and screen for pregnancy and breastfeeding.

Fluorine 18 FDG F18 FDG
19
Feb

Overview

F18 fluorodeoxyglucose is a glucose analog labeled with fluorine 18 used widely for PET imaging of metabolic activity.

Properties

FDG accumulates in tissues with high glucose metabolism; positron emission allows high resolution PET imaging and quantitative SUV analysis.

Uses

Used for oncologic staging and response assessment, infection and inflammation imaging, and selected neurologic and cardiac applications.

Safety

Radiation dose is moderate; ensure appropriate fasting and glucose control prior to injection and follow pregnancy and breastfeeding precautions.

Iodine 123 Ioflupane DaTscan
16
Feb

Overview

Iodine 123 ioflupane is a SPECT radiotracer that binds presynaptic dopamine transporters to assess nigrostriatal integrity.

Properties

I 123 labeled ligand provides high target to background ratio for striatal uptake and is imaged with SPECT cameras several hours after injection.

Uses

Used to support diagnosis of Parkinsonian syndromes versus essential tremor and to evaluate presynaptic dopaminergic neuron loss.

Safety

Administer with thyroid blockade when indicated and follow radiation safety guidelines; consider drug interactions that affect tracer binding.

Iopamidol
8
Feb

Overview

Iopamidol is a nonionic, low osmolar iodinated contrast agent commonly used for intravenous and intraarterial imaging.

Properties

Available in multiple iodine concentrations, radiopaque, and formulated to reduce osmolality related adverse effects compared with older ionic agents.

Uses

Used for CT imaging, CT angiography, myelography and various interventional procedures requiring iodinated contrast.

Safety

Risk of allergic reaction and contrast induced nephropathy exists; screen renal function and hydrate patients as indicated.

Technetium 99m sulfur colloid
7
Feb

Overview

Technetium 99m sulfur colloid is a radiolabeled colloid used in nuclear medicine to image liver, spleen and bone marrow distribution and for gastric emptying studies.

Properties

Colloidal particles labeled with Tc 99m emit gamma photons detected by gamma cameras; particle size influences biodistribution.

Uses

Used for liver spleen scintigraphy, sentinel node mapping in some protocols and gastric emptying or gastric mucosa imaging.

Safety

Radiation exposure is low but present; follow nuclear medicine radiation safety, pregnancy screening and local regulatory requirements.

Contrast Media
4
Feb

Overview

Contrast media enhance visualization of vascular and tissue structures. They include iodinated agents gadolinium based agents and ultrasound contrast. Selection depends on modality and clinical question.

Safety and Reactions

Allergic and idiosyncratic reactions can occur with contrast agents. Screening for risk factors and premedication protocols reduce adverse events. Hydration and renal function assessment are important for iodinated agents.

Dose and Protocols

Contrast dosing and timing affect lesion conspicuity and diagnostic yield. Protocols are tailored to organ system and clinical indication. Optimization balances image quality and patient safety.

Future Innovations

New contrast agents target molecular markers and improve specificity. Lower dose formulations and alternative agents reduce risk. Research explores targeted and theranostic contrast approaches.

Contrast Kidney Safety
4
Feb

Overview

Contrast induced nephropathy risk is mitigated by assessing renal function and hydration. Iodinated contrast and gadolinium based agents require tailored approaches. Risk stratification guides imaging choices and preventive measures.

Assessment

Baseline renal function and risk factors inform contrast decisions. Estimated glomerular filtration rate helps determine safety and need for alternatives. Communication with referring clinicians ensures appropriate planning.

Prevention

Hydration and minimizing contrast dose reduce renal risk in susceptible patients. Use of alternative modalities or non contrast protocols may be appropriate. Post procedure monitoring is considered for high risk individuals.

Policy and Education

Institutional protocols standardize assessment and prevention strategies. Staff education on contrast safety improves adherence to best practices. Documentation of decisions supports quality and medicolegal standards.